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Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the
brainstem of children predominantly between the ages of 6 and 8. Its intricate morphology
and involvement of normal pons tissue precludes surgical resection, and the standard of
care today remains fractionated radiation alone. In the past 30 years, there have been
no significant advances made in the treatment of DIPG. This is largely because we lack
good models of DIPG and therefore have little biological basis for treatment. In recent
years, however, due to increased biopsy and acquisition of autopsy specimens, research
is beginning to unravel the genetic and epigenetic drivers of DIPG. Insight gleaned from
these studies has led to improvements in approaches to both model these tumors in the
lab and to potentially treat them in the clinic. This review will detail the initial strides toward
modeling DIPG in animals, which included allograft and xenograft rodent models using
non-DIPG glioma cells. Important advances in the field came with the development of
in vitro cell and in vivo xenograft models derived directly from autopsy material of DIPG
patients or from human embryonic stem cells. Finally, we will summarize the progress
made in the development of genetically engineered mouse models of DIPG. Cooperation
of studies incorporating all of these modeling systems to both investigate the unique
mechanisms of gliomagenesis in the brainstem and to test potential novel therapeutic
agents in a preclinical setting will result in improvement in treatments for DIPG patients.
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Introduction
Diffuse intrinsic pontine glioma (DIPG) arises in the pons of mostly children and is incurable. Of
the 200–300 new cases of DIPG per year in theUnited States, themedian age at diagnosis is 7 years of
age, and the median survival is<1 year from diagnosis. Surgery is not an option, radiation provides
only temporary relief, and no small molecule or chemotherapeutic agent has been demonstrated to
prolong survival in this disease (1). Until very recently, the choice of drugs to evaluate in clinical
trials for children with DIPG was based on pre-clinical studies in adult glioma models. This was
primarily due to the lack of appreciation that DIPGs may respond differently to therapy than adult
gliomas, as they are genetically distinct and arise in a different microenvironment, as well as the
absence of genetically faithful DIPG pre-clinical models.
Pre-clinical models of glioma have been widely developed and used over the past several decades
in order to study the initiation, progression, and treatment of adult and cerebral cortex gliomas.
However, accumulating evidence of regional differences between DIPG and cerebral cortex glioma
strongly suggests that they arise through distinct tumor driving mechanisms (2–8). Therefore,
translating results of research from adult and cerebral cortex models to treatment strategies for
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DIPG has had little success. All DIPG treatment strategies, to
date, including those based on the results of pre-clinical or clinical
trials with cerebral cortex glioma, have failed to provide improved
efficacy above the radiation standard of care (9). Consequently,
a better understanding of DIPG tumor driving mechanisms is
greatly needed in order to generate more accurate pre-clinical
models of DIPG. Findings using these models will advance the
translation of pre-clinical trials toward efficacious treatments for
patients.
Historically, biopsy procedures were not performed on DIPG
in humans due to the highly sensitive and critical nature of the
brainstem, a tissue boasting very little functional redundancy with
other regions of the brain. Given that surgical resection is not
a part of the standard treatment regimen, acquisition of human
DIPG specimens has been difficult. In recent years, however,
several groups have shown the feasibility and safety associated
with DIPG biopsy (10, 11), as well as the possibility of acquir-
ing DIPG tissue at autopsy of sufficient quality for experimental
purposes (12). This has not only begun to provide tumor spec-
imens to directly generate more accurate cell and animal-based
models but also provided much needed insight into the genetic
alterations driving DIPG. This insight has allowed researchers the
opportunity to genetically model DIPG in animals.
Recent gene expression, mutational, and epigenetic analyses of
DIPG patient samples have revealed distinct subgroups present
within the disease (Figure 1). The earliest studies analyzed gene
expression of both autopsy and surgical patient samples and found
that DIPG gene expression signatures clustered separately from
non-brainstem pediatric high-grade gliomas, and gene set enrich-
ment analysis revealed three distinct subgroups within DIPG
(13). These gene expression subgroups were found to be signif-
icantly similar to the mesenchymal, proliferative, and proneural
groups previously described in adult and non-brainstem pedi-
atric high-grade glioma (14). Further studies have suggested
additional subtypes of DIPG, characterized by upregulation of
MYCN, Hedgehog, and PDGFRA that potentially overlap or fall
outside of the original subgroups (15–18). Most recently, the
identification of novel mutations in histone 3.3/3.1 (5, 8, 17)
and ACVR1 (18–21) further refined the characterization of DIPG
subgroups. The identification of these subgroups and their respec-
tive genetic alterations calls for the development of new pre-
clinical models to accurately represent the unique gene expression
and epigenetic landscapes of DIPG that may impact therapeu-
tic responses.
This review will detail the first attempts at modeling DIPG
in animals, encompassing allograft and xenograft rodent models,
as well as the development of in vitro systems and genetically
engineered models. True improvements in the treatment of this
disease will stem from the cooperation of studies incorporating
all of these modeling systems.
FIGURE 1 | DIPG subgrouping. From high-throughput genetic, epigenetic, proteomic, and sequencing analyses, we map the current understanding of the
interrelated subgroups within DIPG.
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Transplantation-Based Rodent Models
Stereotactic implantation of glioma cells into the rodent brain
has been a widely used tool for glioma research, although the
development of models specifically in the brainstem has lagged
behind those of the cerebral cortex. The first demonstration that
heterotopic cells could grow in the rodent brainstem came from
the injection of human medulloblastoma cells into the cisterna
magna of nude rats, which led to tumor cell colonization in the
medulla andpons (22). This suggested thatmodeling glioma in the
brainstem of rodents might be a feasible experimental approach
for studying the biology and treatment of DIPG, and led others to
investigate this further using adult and neonatal rodents.
The first animal models developed for DIPG specifically
involved the intracranial injection of rat glioma cell lines, F98, 9L,
or C6 into the brainstem of neonatal (23, 24) or adult (25–27)
rats leading to the generation of brainstem glioma (BSG). All of
these allogenic orthotopic models utilized a stereotactic approach
for implantation of the tumor cells into specific coordinates of
the rat brain, targeting the pons. While these rats did develop
tumors resembling gliomas in the appropriate location of the
brainstem, the tumor cells had been derived from adult gliomas
that arose in the cerebral cortex of rats and had been heavily
passaged in culture. Therefore, although these models did take
into account the specific microenvironment of the brainstem, any
innate differences between cerebral cortex glioma and BSG cells
were ignored.
Next, several groups generated human xenograft models in
which human adult cerebral cortex glioblastoma cells, either from
cell lines or serially transplanted xenografts, were transplanted
into the brainstem of rats (28) or mice (29, 30), leading to tumors
histologically and anatomically resembling humanDIPG.As these
tumors were composed of human glioma cells growing within
the brainstem, these models were designed for the purpose of
investigating therapeutic response rates, taking into account the
unique microenvironment and blood–brain barrier of the brain-
stem. One murine xenograft model was used to test the effects
of ionizing radiation (IR), the standard of care for DIPG, and
found that escalating single doses of IR provided a temporary
survival benefit, similar to what is seen in patients (29). Other
studies incorporated bioluminescent imaging in order to show
that treatment with chemotherapeutic agents, such as temozolo-
mide (TMZ), or small molecule inhibitors like PD-0332991 (a
CDK4/6 inhibitor) significantly delayed tumor growth in their
xenograft models (28, 30). These results seem to suggest that TMZ
might be suitable for patients with DIPG; however, clinical trials
have not shown any efficacy (31, 32). This provides evidence that
the use of glioma cells from the cerebral cortex, despite growing
within the brainstem microenvironment, may not be suitable for
predicting clinical response rates of DIPG.
Human DIPG Cell and Xenograft Models
Given the limitations of themodels discussed above, an important
step in the field came when the first group developed human
DIPG-specific cell and xenograft lines derived from autopsymate-
rial of a DIPG patient (33). DIPG autopsy tissue was cultured
in vitro in neural stem cell conditions, which supports the growth
of tumor neurospheres expressing (to varying degrees), Nestin,
GFAP, Vimentin, Sox2, Olig2, and CD133, suggesting a primitive
neural precursor cell type (33). Stereotactic transplantation of
dissociated neurospheres into the fourth ventricle of immunod-
eficient neonatal mice led to the development of tumors in the
hindbrain, diffusely infiltrating the brainstem, cerebellum, and
cerebrum, with histopathology reminiscent of DIPG (33, 34).
Thesewere important studies, as theywere the first to demonstrate
a post-mortem cell culture strategy to generate in vitro neuro-
sphere and in vivo xenograft DIPG models, similar to what has
been well established for cerebral cortex glioma. These studies
were followed by direct implantation of human DIPG cells from
autopsy into mice without a prior culture step, also resulting in
pontine DIPG-like tumors. However, these tumors, through an
unknown mechanism, consisted of cells of murine as opposed to
human origin (34).
These xenograftmodels can be used to evaluate novel treatment
strategies for DIPG – for example, Sewing et al. investigated the
treatment of autopsy-derived xenografts with the chemotherapeu-
tic agent carmustine (BCNU) via convection-enhanced delivery
(CED), showing that this delivery methodmay represent an effec-
tive drug delivery alternative for DIPG patients, bypassing the
restrictive blood–brain barrier (35). One caveat of these models
is that DIPG autopsy material has usually been subjected to radi-
ation treatment as well as additional therapies, such as TMZ (a
known mutagen), avastin, or other experimental agents prior to
harvest, inducing genetic and epigenetic changes in the tumor cells
that will impact therapeutic response.
In contrast to working with autopsy material, models of DIPG
using tissue harvested from living biopsies are beginning to
emerge as the practice of biopsy is becoming more common.
Several groups have developed humanDIPG cell lines from tumor
samples harvested at diagnosis during biopsy procedures (36, 37).
These cell lines were used to test the effects of the targeted agents
dasatinib and cabozantinib in vitro (36), aswell as the combination
of radiation and the Wee1 inhibitor MK-1775 (38). In addition,
these human cell lines can be used to study the biology of DIPG,
as was done by Chan et al. who studied the methylation and gene
expression pattern changes induced by the H3K27M mutation in
tumor cells (39).
Others have implanted DIPG cells collected from biopsy into
mice after in vitro neurosphere culture (37, 40). Specifically,
Thirant et al. injected the cells into the striatum rather than
the brainstem, and Hashizume et al. modified the cells prior
to injection by infecting with hTERT and a luciferase reporter.
The model generated by Hashizume et al. was characterized as
expressing GFAP, Nestin, Olig2, and PDGFRα, similar to human
DIPG. This model was subjected to gene expression and copy
number analysis to compare it to previous analyses of human
DIPG samples (37), and was used as a preclinical tool to test the
in vivo effects of radiation therapy combined with MK-1775 (38).
More recently, Grasso et al. (41) used both autopsy and biopsy
patient-derived DIPG cells to generate in vitro and in vivo model
systems. This study screened 83 drugs and focused on the histone
deacetylase inhibitor panobinostat, one of the most potent drugs
in vitro. Importantly, Grasso et al. found treatment with panobi-
nostat alone significantly reduced orthotopic xenograft growth
and synergized in vitro with the histone de-methylase inhibitor
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GSK-J4, a drug,which had beenpreviously shown to be efficacious
in both cell and xenograft DIPG models (42).
These studies provide important precedent that naïve DIPG
cells from biopsy specimens are able to grow in vitro and be
propagated in immunocompromised mice in vivo. Future work in
this system should be expanded upon to test potential therapeutic
agents or delivery mechanisms. Although biopsy tissue represents
a small sample of the tumor and may not be representative of
the entire tumor, these types of models will perhaps be more
predictive of therapeutic response rates in patients than models
based on autopsy material, as the cells have not been previously
subjected to treatment. Regardless, these human DIPG-derived
cell and xenograft models are much improved over the initial
allograft rodent models, as they are composed of human DIPG
cells and are growing within the unique microenvironment of
the brainstem. The studies described herein using these models
exemplify how xenograft systems can further our understanding
of the mechanisms underlying DIPG tumorigenesis and can be
used as a pre-clinical tool to test potential therapeutics.
Genetically Engineered Models of DIPG
An important complement to human xenografts in mice is the use
of genetically engineered models, as these systems are driven by a
specific set of genetic alterations introduced in a particular cell-of-
origin. The establishment of such models was delayed, however,
by a lack of knowledge regarding the genetic drivers of DIPG. The
increased understanding in recent years of the underlying genetics
of DIPG provides a starting point for genetically modeling these
tumors in the lab.
Genetically engineered mouse models (GEMMs) provide the
advantage of studying tumors that arise in their natural microen-
vironment in immune-proficient animals. The first GEMMs of
DIPG were generated using the RCAS (replication-competent
avian sarcoma-leucosis virus long-terminal repeat with splice
acceptor)/tumor virus A (TVA) modeling system and genetic
alterations commonly found in the human disease (Figure 2) (43–
45). The RCAS–Tva system uses the retroviral avian leucosis and
sarcoma virus family as a gene delivery vector. This virus exclu-
sively infects cells expressing the corresponding surface receptor
TVA, normally expressed in avian cells. Genetically engineered
mice have been generated to express the TVA receptor under
the control of several cell-type specific promoters (46). Using
these mice, the RCAS system revealed gliomas could be generated
targeting cells outside of the subventricular zone (47). This finding
showed the potential of the system to be used for modeling DIPG.
Early work with the RCAS system used germline Ink4a-ARF
loss and PDGFB overexpression targeted to Nestin-expressing
cells of the neonatal mouse pons (44), the likely cells-of ori-
gin for DIPG (33). Tumors arising in this model were located
within the murine brainstem and were histologically similar to
humanDIPG; however, they were not exclusive to the pons region
of the brainstem. Therefore, this system is described as a BSG
GEMM and additional, more spatiotemporally accurate, models
are needed for DIPG. Identification of pons-specific promoters or
enhancers would allow for the generation of mouse strains that
drive expression of Tv-a (for use with the RCA/Tv-a system), Cre,
FIGURE 2 | RCAS-based modeling of DIPG. Schematic of the
RCAS-based GEMM. Individual RCAS plasmids are transfected into virus
producing cells. These cells are then directly injected into the brainstem of
neonatal (Postnatal day 3–4) mice in an even ratio after stable virus production
begins. Viruses selectively infect Nestin-expressing cells lining fourth ventrical
of the brainstem. Tumor symptoms (e.g., loss of balance, enlarged head)
develop within 4–6weeks. Histology using hemotoxylin and eosin (H&E)
staining shows ventral brainstem location of tumor. High magnification (40)
H&E image reveals high-grade tumor characteristics (pseudopalisading
necrosis, mitotic figures, neovascularization), and immunohistochemistry
image shows the HA-tagged H3.3K27M (nuclear) and PDGFB (cytoplasmic)
expressing cells.
or DIPG-specific oncogenes. Alternatively, pons-derived stem
cells can be isolated, cultured, and infected by RCAS viruses
in vitro, and re-introduced into the murine pons as an ex vivo
approach although the in vitro culture conditions will alter the
cells.
Becher et al. (44) was the first to use GEMMs to generate high-
grade BSGs and test for therapeutic response using radiation and
perifosine, an inhibitor of AKT signaling. They found a survival
benefit using a 10Gy radiation dose; however, no additional
benefit was seen using the combined radiation with perifosine
treatment. However, another study using this early GEMM did
demonstrate a survival benefit with the CDK4/6 inhibitor PD-
0332991 alone and in combination with radiation (43). Impor-
tantly, this was the first demonstration of any targeted agent
prolonging survival over radiation therapy alone in a pre-clinical
setting. This early BSG GEMM showed that modeling glioma
in the mouse brainstem was possible and was pivotal in the
identification of a promising new therapy for DIPG.
RCAS-based GEMMs have evolved by utilizing the increas-
ing understanding of DIPG genetic alterations, incorporating the
three most highly recurring genetic alterations: PDGF signaling
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overexpression, p53 loss, and the H3.3K27Mmutation (45). Cells
producing the RCAS-PDGFB, RCAS-Cre, and RCAS-H3.3K27M
viruses were delivered into the brainstem of Nestin-Tva; p53-
floxed neonatal mice and resulted in high-grade BSG with gene
expression similar to human data (Figure 2) (45). This model was
the first to show global loss of H3K27me3 levels with expression
of the K27M mutation, similar to what is seen in patient samples.
The DIPG pre-clinical consortium recently used this GEMM to
test the promising new drug BMS-754807, a potent multi-kinase
inhibitor (48). So far, no survival benefit has been found using the
novel BSGGEMM, but Halvorson et al. showed promising in vitro
data and found the drug concentration levels in treated mice were
well below the known IC-50 for BMS-754807. The aggressiveness
of this most recent BSG GEMM parallels the clinical disease and
represents a good tool for pre-clinical therapeutic trials.
In addition to being used as a pre-clinical tool to test poten-
tial therapeutics for DIPG, GEMMs can be used to study the
biology of the disease in an in vivo setting, which may help
to uncover novel characteristics of the human disease. In this
regard, using the RCAS model described above, comparison of
gene expression profiles of BSGs versus those initiated in the
cerebral cortex revealed that those in the brainstem harbored high
levels of the transcription factor Pax3 (49). In vitro and in vivo
studies suggest that overexpression of this gene contributes to
the gliomagenesis process by inhibiting apoptosis and promoting
proliferation. Analysis of human tumor cohorts showed that 40%
of DIPG patients’ tumors are characterized by particularly high
levels of Pax3, which associates with activation of PDGF signaling,
amplification of cell cycle regulatory genes, and is exclusive of
ACVR1 mutations. This work further defines a subset of human
DIPG (Figure 1) and lends insight into novel mechanisms driving
tumorigenesis.
An additional genetic model recently used human embryonic
stem cells to generate neural precursor-like cells, which were
then transformed with activated PDGFRα, H3.3K27M, and p53
knockdown (50). With these transformed cells, Funato et al. were
able to study the effects of these oncogenes both in vitro and after
transplantation into themouse pons, and found them to cooperate
with one another to induce tumorigenesis. Although the cell-of-
origin used in these studies may not represent a true in vivo cell
of origin for DIPG, this study importantly illustrated the potential
for using data from genomic and expression analysis to model the
genetic drivers of DIPG in vivo using human-derived embryonic
stem cells.
Although recently much progress has been made in the genetic
modeling of DIPG in mice, additional models are needed in order
to more accurately reflect the human disease. As discussed above,
identification of promoters or enhancers specific to the neonatal
pons will allow for the generation of more spatially accurate
tumors. In addition, the RCAS/Tv-a GEMMs discussed herein
effectively model the PDGFRA/oligodendroglial/H3.3K27M sub-
group of DIPG (Figure 1). Utilization of alternative RCAS drivers,
such as H3.1K27M, ACVR1 mutants, or MYCN, is needed in
order to generate accurate models of other subtypes of the disease,
identify underlying biological differences between different sub-
types, and identify subtype-specific therapeutic strategies. Finally,
the current GEMMs for DIPG are based on a neonatal cell-of-
origin; however, we cannot rule out the possibility that DIPG
originates in utero. Thus, introduction of DIPG genetic alterations
to mice in utero via viral infection (including RCAS viruses into
Tv-a transgenic mice) or electroporation [potentially combined
with rising new technologies, such as the Piggybac transposon
system (51)] could lend valuable insight into the effects of DIPG
driver expression before birth.
TABLE 1 | Animal models of DIPG.
Model Rationale Method Description Reference
F98, 9L, and C6 rat
brainstem glioma
Use of rodent cerebral glioma
cell lines to create tumors in
the brainstem
Allosteric, orthotopic, stereotactic
injection
Rodent cortical glioma cell lines
transplanted into the rat or mouse
pons
(23–27)
Cerebral xenograft Human cerebral glioma cells
used to generate tumors in
rodent brainstem
Stereotactic injection of adult
cerebral cortex glioma cells
Patient-derived cortical
glioblastoma cells are introduced
into the rodent brainstem
(28–30)
DIPG Xenograft Autopsy or biopsy-derived
patient DIPG cells used to
propagate murine tumors for
drug testing
Stereotactic injection of human
DIPG cells
Autopsy and biopsy-derived
patient DIPG cells are used for
injection into rodent brainstem
(33–39, 41)
DIPG cell lines DIPG patient cells cultured
in vitro for use in drug
screening and general
research
Isolated human DIPG cells cultured
in stem cell conditions
Autopsy and biopsy-derived
patient DIPG cells are cultured
in vitro under stem/progenitor
conditions
(33, 34, 36–39, 41)
RCAS GEMMs Use of transgenic mice with
introduced genetic alterations
found in DIPG as pre-clinical
models
Genetically engineered mouse
models using retroviral gene
delivery targeting the mouse
brainstem
Transgenic mice expressing RCAS
viral receptor under cell-type-
specific promoters are infected
with oncogenes important in DIPG
(41, 43, 44, 46, 47)
Human embryonic stem
cells
Development of human
derived puripotent stem cells
for modeling DIPG
Human embryonic stem cells are
differentiated to a neuronal
progenitor lineage and
co-transduced with common DIPG
alterations
In vitro derived neuronal
progenitors are transduced with
constitutively active PDGFRA, p53
shRNA, and H3.3K27M for in vitro
analysis or murine implantation
(50)
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Conclusion
Pre-clinical models of DIPG are continuing to improve as our
knowledge of DIPG etiology expands. The current models each
have advantages to their use and have all contributed invaluable
insight into DIPG biology and treatment (Table 1). Human cell
and xenograft models have the benefit of being derived directly
from DIPG patients. Cell lines derived from autopsy are likely
altered by treatment, and thus, biopsy-derived cell lines, although
rare, are biologically superior for identifying novel agents to treat
newly diagnosed tumors. Treatment-related alterations found
in autopsy samples, however, are valuable tools, which, when
compared to pre-treatment tissue may provide insight into the
changes occurring in DIPG cells in response to therapy, including
metabolic changes, additional mutations, and the expansion of
tumor subpopulations. These observations could provide both
explanations for the failure of attempted therapies and strategies
for combating therapeutic resistance.
Xenografts of human cells into immunocompromised mice
also retain the advantage of using patient-derived cells. However,
full recapitulation of human tumor development is compromised
by the alteration of tumor microenvironment and absence of an
immune system. Therefore, GEMMs are an important comple-
ment to human xenograft models, and while they have shown
much promise, they remain underdeveloped. The next generation
of GEMMs should incorporate the knock-in of common DIPG
mutations, such as H3.3K27M, into the endogenous loci in order
to better simulate the expression level and localization of the
mutated gene products. Additionally, while current GEMMs use
overexpression of PDGFB ligand as an oncogenic driver, ampli-
fication of the wild-type PDGFRα receptor is most common in
patients (13). Therefore, a GEMM incorporating amplification of
PDGFRα will be another improvement for future development,
as will models incorporating oncogenic drivers found in the other
subtypes of DIPG.
The increased development and availability of cell mod-
els, xenografts, and GEMMs of DIPG represent great promise
to improve the treatment of this deadly disease. While the
path from development of genetically faithful animal models
to generation of efficacious therapies can be long and ardu-
ous, continuing to improve the models as more information
about the human disease is uncovered is necessary. Using the
available tools to identify novel therapeutic agents and causes
of therapy resistance will be paramount in developing effec-
tive treatment strategies. Cooperation between researches utiliz-
ing all of the available pre-clinical models discussed here will
be the key to advancement in this field. These models repre-
sent valuable tools, which will aid in testing future therapeutic
agents and lend further insight into the biological mechanisms
of DIPG.
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